Barco N.V.

Barco reported first-half 2026 orders of EUR 468 million, down 4% year over year, or flat at constant currency. Sales were EUR 418 million, down 8% reported and 3% at constant currency. EBITDA came in at EUR 26 million, equal to 6% of sales, while net result was -EUR 4.8 million. Gross profit margin was described as resilient despite mix effects, and recurring revenues reached 13% of sales. Free cash flow was -EUR 37 million, driven mainly by higher inventories, and net debt was EUR 33 million at mid-year after the VerVent acquisition, dividends, and buybacks. For 2026, management reaffirmed full-year sales above last year, including VerVent, and an EBITDA margin of 11% to 12%.

CEO An Steegen emphasized that the second quarter improved after a difficult first quarter, with orders picking up toward the end of Q2. She framed the quarter as evidence that Barco’s strategy is working: more software, more recurring revenue, and a broader entertainment platform after adding VerVent. Her tone was constructive but realistic, highlighting both strong areas like control rooms, diagnostic imaging, and cinema, and weaker spots such as BYOD in meeting experience and surgical healthcare.

CFO Ann Desender focused on the bridge to lower earnings: FX took about EUR 3 million off EBITDA, lower volumes hurt operating leverage, and one-offs from prior-year acquisition accounting and U.S. grants also mattered. She pointed to gross profit margin resilience, helped by more sales/service and recurring revenue, which now represent 13% of sales, and said cost actions taken in Q2 should have a larger impact in the second half. On cash, she said free cash flow was -EUR 37 million because inventories increased by EUR 57 million, including component and memory-chip prebuys, while capex was EUR 15 million and restructuring costs totaled EUR 8.4 million, with about EUR 1 million cash effect.

Analysts pressed management on how the company can reach the implied second-half guidance ramp; management said the case depends on six months of VerVent, better momentum in the top line, resilient margins, and cost actions that will show more in H2. Questions also focused on the acquisition price of VerVent, which management said was not cheap but was justified by the revenue multiple, the expected synergy of combining visualization and audio, and the early positive contribution. In healthcare, an analyst asked why surgical contracts are not being replaced and whether moving to mid-range solutions would pressure margins; management said large contracts take time to redesign and certify, and that using lower-cost components and R&D in China should help protect margins even in entry-level products.